Mangoceuticals, INC Form 4 insider transactions

Nuclea Energy Inc. and Mangoceuticals, Inc. have entered a definitive agreement to combine, aiming to list Nuclea's advanced nuclear technology on Nasdaq and fund its Morpheus microreactor development.

Mangoceuticals, Inc. announced a business combination agreement with Nuclea Energy Inc. to advance Nuclea's lead-cooled Morpheus microreactor technology.

MANGOCEUTICALS, INC. CEO Jacob D. Cohen increased his beneficial ownership through a discretionary bonus, new stock options, and a convertible note with warrants.

MANGOCEUTICALS, INC. CEO Jacob D. Cohen's stock options were repriced to $0.45 per share on March 16, 2026, a significant reduction from original strike prices, though still above the market closing price.

MANGOCEUTICALS, INC. CFO Eugene M Johnston reported the sale of 3,333 shares of common stock at $1.1653 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

MANGOCEUTICALS, INC. CFO Eugene M. Johnston sold 5,000 shares of common stock for $1.195 per share as part of a pre-arranged 10b5-1 trading plan.

MANGOCEUTICALS CFO Eugene M Johnston sold 10,000 shares of common stock on December 5, 2025, for a weighted average price of $1.128 per share.

MANGOCEUTICALS, INC. Director Alex P. Hamilton sold 125,000 shares of common stock at a weighted average price of $1.223 per share.

MANGOCEUTICALS, INC. CEO Jacob D. Cohen received a discretionary bonus of 200,000 common shares, aligning his interests with shareholders.

MANGOCEUTICALS, INC. Chief Financial Officer Eugene M. Johnston received a grant of 100,000 shares of common stock as compensation.

MANGOCEUTICALS, INC. Director Lorraine Pamela D'Alessio was granted 100,000 shares of common stock as a discretionary bonus for her board services.

MANGOCEUTICALS, INC. Director Alex P. Hamilton was granted 100,000 shares of common stock as a discretionary bonus for services rendered.

MANGOCEUTICALS, INC. Director Kenny Myers was granted 100,000 shares of common stock as a discretionary bonus for his services.

Director Kenny Myers reports acquiring 25,000 shares of Mangoceuticals common stock as a bonus and disposing of 36,667 shares.

Director Alex P. Hamilton reports acquiring 25,000 shares of Mangoceuticals common stock as a bonus and disposing of 28,334 shares.

Antonios Isaac, President of Mangoceuticals, acquires 60,000 shares of common stock as a discretionary bonus for services rendered.

Director Lorraine Pamela D'Alessio reports acquisition of 25,000 shares of Mangoceuticals stock as a bonus and disposal of 36,667 shares.

Jacob Cohen, CEO of Mangoceuticals, received 200,000 shares as a bonus and reported changes in his and The Tiger Cub Trust's beneficial ownership of the company's stock.

Mangoceuticals' Chief Financial Officer, Eugene M. Johnston, acquired 25,000 shares and disposed of 38,334 shares of common stock on November 11, 2024.

Mangoceuticals CEO Jacob D. Cohen transferred 800,000 shares of common stock to The Tiger Cub Trust, a trust he controls, without altering beneficial ownership.

Director Alex P. Hamilton sold shares of Mangoceuticals, Inc. (MGRX) on June 25 and June 26, 2024.

Amanda Hammer, Chief Operating Officer of Mangoceuticals, acquired 100,000 shares of common stock on June 3, 2024, as compensation for services rendered.

Alex P. Hamilton, a director of Mangoceuticals, Inc., acquired 100,000 shares of common stock on June 3, 2024, as compensation for services rendered.

Kenny Myers, a director at Mangoceuticals, acquired 100,000 shares of common stock as compensation for board services.

Mangoceuticals CEO Jacob D. Cohen receives 800,000 shares as a bonus for fiscal year 2024.

Lorraine Pamela D'Alessio, a director at Mangoceuticals, Inc., acquired 100,000 shares of common stock as compensation for services rendered as a board member.